In a report released today, Markus Mayer from Baader Bank maintained a Buy rating on LANXESS (LNXSF – Research Report), with a price target of EUR65.00. The company’s shares closed last Thursday at $48.48.
Mayer has an average return of 0.1% when recommending LANXESS.
According to TipRanks.com, Mayer is ranked #371 out of 7952 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for LANXESS with a $63.87 average price target, a 31.7% upside from current levels. In a report issued on May 27, Jefferies also maintained a Buy rating on the stock with a EUR48.50 price target.
Based on LANXESS’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.08 billion and net profit of $29 million. In comparison, last year the company earned revenue of $1.69 billion and had a net profit of $64 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LANXESS AG is a holding company, which engages in the provision of specialty chemicals. It operates through the following segments: Advanced Intermediates, Specialty Additives, Performance Chemicals, High Performance Materials, and Arlanxeo. The Advanced Intermediates segment consists of industrial chemical intermediates and a key player in the custom synthesis, and manufacturing of chemical precursors and specialty active ingredients. The Specialty Additives segment focuses on specialty additive chemicals. The Performance Chemicals segment covers application-oriented process, and functional chemicals operations. The High Performance Materials segment represents plastic activities in the engineering materials. The Arlanxeo segment refers to synthetic rubber activities. The company was founded on July 1, 2004 and is headquartered in Leverkusen, Germany.
Read More on LNXSF:
- Walmart Is Launching 4 New High-Tech Centers; Street Remains Positive
- Square Teams Up with Apple for “Tap to Pay”
- Pfizer Will Exit GSK’s Consumer Health Business Haleon Upon Listing
- Gravity Survey Unveils Second Potential Salt Dome in SALT’S Bay St. George District
- Zealand Pharma completes registration of capital increase